IVERIC bio, Inc. (NASDAQ:ISEE) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) have been given an average rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $26.00.

A number of research firms have weighed in on ISEE. Stifel Nicolaus increased their target price on IVERIC bio from $28.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, September 8th. Morgan Stanley raised their price objective on IVERIC bio from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Credit Suisse Group raised their price objective on IVERIC bio to $27.00 in a research note on Tuesday, September 6th. Bank of America assumed coverage on IVERIC bio in a research note on Wednesday, June 8th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Robert W. Baird raised their price objective on IVERIC bio from $27.00 to $34.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 7th.

IVERIC bio Price Performance

Shares of NASDAQ:ISEE opened at $17.62 on Monday. IVERIC bio has a 1 year low of $8.85 and a 1 year high of $20.99. The stock’s fifty day moving average price is $12.65 and its 200-day moving average price is $12.96. The company has a market cap of $2.08 billion, a P/E ratio of -14.44 and a beta of 1.55.

IVERIC bio (NASDAQ:ISEEGet Rating) last posted its earnings results on Tuesday, July 26th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter in the prior year, the company earned ($0.32) earnings per share. On average, sell-side analysts anticipate that IVERIC bio will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Christopher Paul Simms sold 12,272 shares of the stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $11.25, for a total transaction of $138,060.00. Following the completion of the sale, the senior vice president now owns 28,547 shares in the company, valued at $321,153.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other IVERIC bio news, EVP Anthony S. Gibney sold 7,791 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $9.41, for a total transaction of $73,313.31. Following the completion of the transaction, the executive vice president now owns 10,959 shares in the company, valued at approximately $103,124.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christopher Paul Simms sold 12,272 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $11.25, for a total value of $138,060.00. Following the transaction, the senior vice president now owns 28,547 shares of the company’s stock, valued at approximately $321,153.75. The disclosure for this sale can be found here. 2.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IVERIC bio

Institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors grew its holdings in IVERIC bio by 14,900.0% during the 1st quarter. Captrust Financial Advisors now owns 1,500 shares of the company’s stock valued at $25,000 after buying an additional 1,490 shares in the last quarter. Vectors Research Management LLC purchased a new position in shares of IVERIC bio in the 2nd quarter worth approximately $29,000. Point72 Hong Kong Ltd purchased a new position in shares of IVERIC bio in the 4th quarter worth approximately $40,000. Nisa Investment Advisors LLC boosted its holdings in shares of IVERIC bio by 39.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,520 shares of the company’s stock worth $43,000 after purchasing an additional 1,290 shares during the period. Finally, Macquarie Group Ltd. boosted its holdings in shares of IVERIC bio by 679.5% in the 2nd quarter. Macquarie Group Ltd. now owns 8,005 shares of the company’s stock worth $77,000 after purchasing an additional 6,978 shares during the period.

IVERIC bio Company Profile

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Read More

Analyst Recommendations for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.